Table II.
Association between MUC1-Tn expression and clinicopathological features in patients with lung ADC.
| Variables | No. of cases | No. of cases with high MUC1-Tn expression, n (%) | P-valueb |
|---|---|---|---|
| All lung ADC cases | 175 | 44 (25.1) | |
| Age, years | |||
| ≤68 | 92 | 22 (23.9) | 0.690 |
| >68 | 83 | 22 (26.2) | |
| Sex | |||
| Male | 84 | 28 (33.3) | 0.016d |
| Female | 91 | 16 (17.6) | |
| Smoking statusc | |||
| Current or ex-smoker | 107 | 34 (31.8) | 0.005d |
| Non-smoker | 64 | 8 (12.5) | |
| NA | 4 | 2 (50.0) | |
| pT statusa | |||
| pT1a-c | 111 | 18 (16.2) | <0.001d |
| pT2a-b+pT3+pT4 | 64 | 26 (40.6) | |
| pN statusa | |||
| pN0 | 144 | 34 (23.6) | 0.314 |
| pN1-2 | 31 | 10 (32.3) | |
| Pleural invasion | |||
| Negative | 130 | 26 (20.0) | 0.008d |
| Positive | 45 | 18 (40.0) | |
| Lymphatic invasionc | |||
| Negative | 29 | 14 (48.3) | <0.001d |
| Positive | 64 | 9 (14.1) | |
| NA | 82 | 21 (25.6) | |
| Vascular invasionc | |||
| Negative | 27 | 12 (44.4) | 0.005d |
| Positive | 66 | 11 (16.7) | |
| NA | 82 | 21 (25.6) | |
| Pre-op Serum CEA level, ng/ml | |||
| ≤5.0 | 108 | 20 (18.5) | 0.010d |
| >5.0 | 67 | 24 (35.8) | |
| Pre-op Serum CYFRA21-1 levelc, ng/ml | |||
| ≤2.1 | 125 | 25 (20.0) | 0.014d |
| >2.1 | 44 | 17 (38.6) | |
| NA | 6 | 2 (33.3) | |
a
TNM classification system of the Union for International Cancer Control (8th edition) (18).
b
The values of the patients with high MUC1-Tn and the patients with moderate/low MUC1-Tn were compared using a χ2 test.
c
The values (except NA data) of the patients with high MUC1-Tn and the patients with moderate/low MUC1-Tn were compared using a χ2 test.
d
P<0.05. MUC1, mucin 1; ADC, adenocarcinoma; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragment; Pre-op, preoperative; NA, not available.